Bioanalytik-Münster News

28.10.2022 - New ETPN webinar on Nanotoxicology, Dec. 1, 2022

Register for free

Dear colleagues from the European Nanomedicine community,

We are glad to invite you all to the next ETPN webinar: "Nanotoxicology revisited: From in vivo findings to in vitro testing, the NanoBioQuant Project." feat. Prof. Martin Wiemann (IBE R&D gGmbH) to be held on Dec. 1, 2022 at 5PM (CET).

How to join the webinar

This webinar is accessible to all for free, upon mandatory registration by clicking on this link.
Remark: you might have to login to your Zoom account to access the event.


The assessment of the safety of nanomaterials (NM) and nanotechnology products is based on toxicological studies that need to be in accordance with regulatory criteria. In this context, the distribution of NM in the organism plays a key role in understanding NM effects. Although it is now known that inhaled NM can reach organs such as liver, spleen and kidney NM, studies on the localization of NM within these organs are lacking. Which cell types take up or accumulate nanomaterials? And what effects can be expected as a result?

To clarify these questions, studies on NM’s organ distribution were carried out for the first time secondary to a long-term inhalation of low NM concentrations. In the 3 years-project NanoBioQuant project partners (funded by BMBF) tested and optimized analytical methods for the detection of nanomaterials in tissues. Cell types that take up or accumulate nanomaterials were identified and provided the basis for cell models with the help of which biological effects of NM were investigated. The overall goal was to transfer NM concentrations found in the organ to these cell models. The presentation will touch upon state-of-the-art  mass spectroscopic techniques for the spatially resolved detection of organic and inorganic NM and on label-free microscopy techniques.


Prof. Martin Wiemann studied biology, botany and biochemistry and was a human physiologist at the University of Duisburg-Essen, Germany (habilitation)  before he became head of the IBE R&D Institute for Lung Health in 2007. Since then, he develops in vitro methods for the prediction of (nano)particle toxicity in the lung.

About IBE

The company IBE R&D gGmbH is focussing on the toxicological description of micron- and nano-sized particles. Research is mostly carried out in publicly funded projects (such as NanoCare, NanoGEM, NanoBioDetect, NanoBioQuant, Refine, MACRAME). Research projects are also conducted together with selected industrial partners and the company's activities have often led to bridges between universities and Industry. As a private non-profit institute we are publishing our results in scientific journals.


Alexandre Ceccaldi
General secretary of ETPN
Coordinator of the H2020 NOBEL project.
European Technology Platform on Nanomedicine